Anamnestic response to administration of purified non-adsorbed hepatitis B surface antigen in healthy responders to hepatitis B vaccine with long-term non-protective antibody titres

Vaccine

Volumn 20, Issue 31-32, 2002, Pages 3725-3730

  Dentico, Pietro ^a   Crovari, Pietro ^b   Lai, Piero Luigi ^b   Ponzio, Franca ^c   Safary, Assad ^d   Pellegrino, Anna ^a   Meurice, Francois ^d   Di Pasquale, Alberta ^d   Tornieporth, Nadia ^d   Volpe, Anna ^a   Icardi, Giancarlo ^b  

^a UNIVERSITY OF BARI   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c GSK   (Italy)

^d GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Anamnestic response; Low anti HBs titres; Purified non adsorbed HBsAg administration

Indexed keywords

HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT VACCINE;

ADULT; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HEPATITIS B; HUMAN; HUMAN EXPERIMENT; IMMUNOLOGICAL MEMORY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; VACCINATION; ADOLESCENT; ADSORPTION; BIOSYNTHESIS; BLOOD; HEPATITIS B VIRUS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADSORPTION; ADULT; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; IMMUNOLOGIC MEMORY; MALE; MIDDLE AGED; VACCINES, SYNTHETIC;

EID: 0036839466     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00356-0     Document Type: Article

References (27)

1. Aspinall S., Kocks D.J. Antibody decline after hepatitis B vaccination and the effects of boosters. S. Afr. Med. J. 85(4):1995;283-284.
2. Tilzey A.J. Hepatitis B vaccine boosting: the debate continues. Lancet. 345(8956):1995;1000-1001.
3. Mcintyre P.G. Hepatitis B vaccination follow-up. Lancet. 345(8964):1995;1575.
4. Kane M., Banatvala J., Da Villa G.et al. Are booster immunisations needed for lifelong hepatitis B immunity? Lancet. 355(9203):2000;561-565. (Consensus Committee).
5. Banatvala J., Van Damme P., Oehen S. Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory. Vaccine. 19:2000;877-885.
6. Averhoff F., Mahoney F., Coleman P., Schatz G., Hurwitz E., Margolis H. Immunogenicity of hepatitis B vaccines: implications for persons at occupational risk of hepatitis B virus infection. Am. Prev. Med. 15:1998;1-8.
7. Greenberg D.P. Pediatric experience with recombinant hepatitis B vaccines and relevant safety and immunization studies. Pediatr. Infect. Dis. 12:1993;438-445.
8. Belloni C., Chirico G., Pistorio A., Orsolini P., Tinelli C., Rondini G. Immunogenicity of hepatitis B vaccine in term and pre-term infants. Acta Paediatr. 87:1998;336-338.
9. Lakshmi G., Reddy R.P., Kumar K.K., Bhavani N.V., Daynand M. Study of safety, immunogenicity and seroconversion of hepatitis B vaccine in malnourished children of India. Vaccine. 18:2000;2009-2014.
10. West D.J., Calandra G.B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine. 14:1996;1019-1027.
11. Van Herck K., Van Damme P., Thoelen S., Meheus A. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8 years results. Vaccine. 16:1998;1933-1935.
12. Garcia Llop L., Asensi Alcoverro A., Coll Mas P., Grafia J.C. Anti-HBs titer after vaccination program in children and adolescent. Should a booster dose be given? An Esp. Pediatr. 54:2001;32-37.
13. Tanzi M.L., Veronesi L., Nieddu A., Camarlengo P., Boccelli V., Bellelli E. Measurement of anti-HBs antibodies in a population of 18 years old 6 years after the primary vaccination series. Ann. Ig. 12:2000;265-271.
14. Velinga A., Van Damme P., Bruckers L., Weyler J.J., Molenberghs G., Meheus A. Modeling long-term persistence of hepatitis B antibodies after vaccination. J. Med. Virol. 57:1999;100-103.
15. CDC. Recommendation for preventing transmission of infections among chronic hemodialysis patients. MMWR 2001, 50 RR-5.
16. Oon LL, King A, Higgins JA, Lee CA, Kernoff PB, Goodall AH. Protective antibodies to hepatitis B virus in haemophilics. J Med Virol 1991;19-25.
17. Hauser P., Voet P., Simoet E., Thomas H.C., Petre J., De Wilde M.et al. Immunological properties of recombinant HBsAg produced in yeast. Postgrad. Med. J. 63:1987;S83-S91.
18. Vellinga A., Van Damme P., Weyler J.J., Vranckx R., Meheus A. Hepatitis B vaccination in mentally retarded: effectiveness after 11 years. Vaccine. 17(6):1999;602-606.
19. Poovorawan Y., Sanpavat S., Pongpunglert W.et al. Long term efficacy of hepatitis B vaccine in infants born to hepatitis B e antigen-positive mothers. Pediatr. Infect. Dis. J. 11(10):1992;816-821.
20. Poovorawan Y., Sanpavat S., Chumdermpadetsuk S., Safary A. Long term hepatitis B vaccine in infants born to hepatitis B e antigen positive mothers. Arch. Dis. Child Fetal. Neonatal. 77(1):1997;F47-F51.
21. Poovorawan Y., Theamboonlers A., Sanpavat S.et al. Long-term antibody persistence after booster vaccination with combined tetravalent diphtheria, tetanus, whole-cell Bordetella pertussis and hepatitis B vaccine in healthy infants. Ann. Trop. Paediatr. 17:1997;301-308.
22. Hoofnagle J.H. Type B hepatitis: virology, serology and clinical course. Sem Liver Dis. 1981:1981;102-109.
23. Thomssen R, Gerlich W, Stamm B, et al. Infectivity of purified hepatitis B virus particles. New Engl J Med 1977;396.
24. Shikata T., Karasawa T., Abe K.et al. Hepatitis B e antigen and infectivity of hepatitis B virus. J. Infect. Dis. 136(4):1977;571-576.
25. Whalley S.A., Murray J.M., Brown D.et al. Kinetics of acute hepatitis B infection in humans. J. Exp. Med. 193(7):2001;847-854.
26. Leroux-Roels G, Rehermann B, Koutsoukos M, et al. Characterization of humoral and cellular immune responses induced by a therapeutic vaccine for the treatment of chronic Hepatitis B. In: Proceedings of Communication at the 10th International Symposium on Viral Hepatitis and Liver Disease, Atlanta, April 2000.
27. Grubeck-Loebenstein B, Wick G. In: Proceedings of a Symposium on Immunosenescence: a Major Cause of Disease in the Elderly from Molecules to Patients (Summary). Exp. Gerontol. 1999;34(3):407-11.